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2 Normal tissue samples are often employed as a control for understanding disease mechanisms, 1 however, collecting matched normal tissues from patients is difficult in many instances. In cancer 2 research, for example, the open cancer resources such as TCGA and TARGET do not provide 3 matched tissue samples for every cancer or cancer subtype. The recent GTEx project has profiled 4 samples from healthy individuals, providing an excellent resource for this field, yet the feasibility 5 of using GTEx samples as the reference remains unanswered. 6 7 Methods 8
We analyze RNA-Seq data processed from the same computational pipeline and systematically 9 evaluate GTEx as a potential reference resource. We use those cancers that have adjacent 10 normal tissues in TCGA as a benchmark for the evaluation. To correlate tumor samples and 11 normal samples, we explore top varying genes, reduced features from principal component 12 analysis, and encoded features from an autoencoder neural network. We first evaluate whether 13 these methods can identify the correct tissue of origin from GTEx for a given cancer and then 14
seek to answer whether disease expression signatures are consistent between those derived 15 from TCGA and from GTEx. 16 17
Results 18
Among 32 TCGA cancers, 18 cancers have less than 10 matched adjacent normal tissue 19 samples. Among three methods, autoencoder performed the best in predicting tissue of origin, 20 with 12 of 14 cancers correctly predicted. The reason for misclassification of two cancers is that 21 none of normal samples from GTEx correlate well with any tumor samples in these cancers. This 22 suggests that GTEx has matched tissues for the majority cancers, but not all. While using 23 autoencoder to select proper normal samples for disease signature creation, we found that 24 disease signatures derived from normal samples selected via an autoencoder from GTEx are 25 consistent with those derived from adjacent samples from TCGA in many cases. Interestingly, 26 3 choosing top 50 mostly correlated samples regardless of tissue type performed reasonably well 1 or even better in some cancers. 2 3 Conclusions 4
Our findings demonstrate that samples from GTEx can serve as reference normal samples for 5 cancers, especially those do not have available adjacent tissue samples. A deep-learning based 6 approach holds promise to select proper normal samples. 7
Background 8 9
Comparing molecular profiles of disease tissue samples and normal tissue samples is often 10 employed to identify a signature of the disease. The signature defined as differentially expressed 11 genes between two groups is critical to understanding abnormal disease features and guiding 12 therapeutic discovery [1] [2] [3] [4] [5] [6] . For example, a gene expression signature created from the 13 comparison of liver cancer tumor samples and adjacent tissue samples was used to discover anti-14 parasite drugs as therapeutics for liver cancer [7] . Analysis of matched tumor and normal profiles 15 identified common transcriptional and epigenetic signals shared across cancer types [8] . scale integrative analysis of cancer profiles, cellular response signatures and pharmacogenomics 17 data suggested that such disease signatures can be widely employed for screening anti-cancer 18 drugs [9] . 19 20 However, there are many lingering issues that hinder these types of analyses. For instance, in 21 many cancers, adjacent normal tissues are not available in these genomic databases such as 22
The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research To Generate 23 Effective Treatments (TARGET) ( Figure 1A ). As such, there is an open question on what tissue 24 4 samples should be selected for these scenarios or whether creation of a proper disease signature 1 is even possible. The recent Genotype-Tissue Expression (GTEx) project [10] has profiled 2 samples from healthy individuals, providing an excellent resource. However, their profiles are 3 generated from different studies and processed under different computational approaches, the 4 feasibility of using GTEx samples as the reference remains unanswered. Moreover, given the fact 5 there is heterogeneity within a disease, another goal is to determine a set of normal samples that 6 are optimal for use as the reference for a group of patient samples. One approach is to choose 7 normal samples that are similar to disease samples based on their gene expression profiles. As 8 a substantial number of genes that are lowly expressed or not expressed at all add noises in 9 similarity measurement, one typical alternative strategy is to utilize the top varying genes across 10 disease samples as the features for similarity measurement. However, selecting top varying 11 genes may ignore information of many critical genes. 12
13
In this work, we use the RNA-Seq data processed from the UC Santa Cruz Computational 14 Genomics Lab's Toil-based RNA-seq pipeline [11] and systematically evaluate GTEx as a 15 potential reference resource ( Figure 2 ). We use those cancers that have adjacent normal tissues 16 in TCGA as the benchmark for the evaluation. We also explore the potential use for state-of-the-17 art deep learning models, specifically layers of autoencoders, to create reduced features for 18 similarity measurement. We found that disease signatures derived from normal samples in GTEx 19 are consistent with those derived from adjacent samples in TCGA in many cases. Our findings 20 demonstrate that samples from GTEx can serve as reference samples for the majority of cancers, 21 but not all. Additionally, we show promising results for utilizing deep learning strategies to select 22 reference tissues. 23 24 25 5 Methods 1 2 Datasets 3 TCGA (https://cancergenome.nih.gov/) is a public repository of genomics data (e.g., gene 4 expression) for cancer, and sometimes adjacent normal tissues. TARGET is a similar resource 5 focused on childhood cancers. The GTEx project is a collection of gene expression data for over 6 7700 healthy individuals for over 50 tissues. In the current study, raw counts data and phenotype 7 metadata for the analysis were downloaded from UCSC Xena Treehouse 8 (https://xenabrowser.net/datapages/?cohort=TCGA%20TARGET%20GTEx) and processed into 9 an R dataframe consisting of studies from TCGA, TARGET, and GTEx, with a total of 58,581 rows 10 of gene expression raw counts (identified as HUGO gene symbols). Transcript abundance 11 estimated from STAR and RSEM was used. The Treehouse raw counts data consist of 19,249 12 samples and, of those, a total of 19,131 tissue samples were annotated with phenotype metadata. 13
We only used tissue samples with annotated metadata for this analysis. Of the 32 cancers, we 14 chose cancers that have at least 10 case-control (tumor-adjacent normal) sample pairs ( Figure  15 1). 16
Workflow 17 18 In our study, we first evaluate whether our approach can identify the correct tissue site from GTEx 19 for a given cancer ( Figure 2 ). We then ask whether disease signatures are consistent between 20 those derived from TCGA and from GTEx. First we selected tissues for a particular cancer in the 21 TCGA dataset and performed quality control by filtering for tumor purity > 0.7 as determined by 22 ESTIMATE [12] . Tissue outliers were determined by computing the principal component analysis 23 6 of tissues and filtering out those with absolute z-score of the first component of greater than 3. 1 Reference normal tissue for the tumor samples were computed using four methods: 2 a. Random Method: Random selection of 50 GTEx normal tissues. After the reference GTEx tissues were selected, we again removed tissues for outliers based on 15 computed first PCA > 3. Then the tumor tissues and reference tissues were normalized using the 16 RUVg R package library [13] . Differential expression was computed on the normalized samples. 17
We analyzed each differential expression of the computations by comparing it with differential 18 expressions computed from case-control set. The signature genes selected for analysis had an 19 absolute log fold change of greater than 1 and adjusted p-value of less than 0.001. 20 21 First, we performed differential expression analysis by comparing tumor samples and normal 22 samples using edgeR [14] . While we chose edgeR only to use, our preliminary assessment 23 showed the conclusions hold using Limma + voom [15] We use two cancers as examples for further in-depth analyses, specifically Hepatocellular 5 Carcinoma (HCC) and Bladder Urothelial Carcinoma (BUC). In our prior results, we found that 6 using more genes to compute the correlation generally helped to select the correct tissue site for 7 the tumor. We ran correlation for each site using increasing number of varying genes as well as 8 autoencoder features. We normalize the correlation of the cancer site liver ( Figure 5A ). We found 9 that as the number of genes used increases all tissues will generally converge to have higher 10 correlation with the disease tissue, this may be due to including genes of conserved regions or 11 low expressions. Using all features from the autoencoder allows us to have much better 12 separation of the site liver from other non-related sites of the cancer, indicating autoencoder 13 captures the biology of disease sample more specifically ( Figure 5B -C). 14
15
For BUC, however, the varying genes method was unable to determine bladder as the best site 16 instead choosing esophagus ( Figure 6A -B). Increasing varying genes from 100 to 40,000 brought 17 down the correlation of esophagus site relative to bladder, however, it brought up correlation of 18 other tissue sites relative to bladder ( Figure 6A ) similar to what we see in Figure 5A . This suggests 19 that naively increasing varying genes does not help to distinguish tissue site selection. Meanwhile, 20 the autoencoder method correctly predicts bladder as the top site with great separation between 21 bladder and esophagus with greater distinction ( Figure 6A , Figure 6C ). Notably, the correlation in 22 BUC is lower than that in HCC based on different similarity metrics. This suggests that cell 23 composition in bladder tissues may be more diverse. As we have demonstrated that gene expression profiles can be used to identify tissue of origin, 3
we then asked if these samples sharing the same tissue of origin from GTEx can substitute 4 adjacent tissues from TCGA to create disease signatures. We employed three approaches to 5 select samples ( Figure 2 ). We evaluate consistency based on the significance of overlap between 6 signatures and correlation of fold changes of common signature genes. 7 8 Figure 7 shows the rank-based correlation of differential expression between consensus 9 transcripts for each cancer from TCGA using GTEx reference tissue vs. TCGA case-control 10 samples. Using the average of three random tissue site selection as our baseline we see that our 11 other strategies are superior. The autoencoder produced better correlations overall regardless of 12 sample selection method. 13 14 For the autoencoder, it seems that choosing all samples from the same tissue of origin performs 15 slightly better than choosing 25 percentile and above mostly correlated samples from the same 16 tissue of origin. Interestingly, choosing top 50 mostly correlated samples from any tissue performs 17 reasonably well or even better in some cancers, where the tissue of origin was misclassified such 18 as the varying genes method for stomach adenocarcinoma ( Supplementary Table 1 ). This is very 19 significant because in many cases, where we may have no or an insufficient number of matched 20 normal tissues, we may use normal samples from other sites. For example, in the three kidney 21 cancers: Kidney Clear Cell Carcinoma, Kidney Papillary Cell Carcinoma and Kidney 22
Chromophobe, our analysis suggests three cancers can share the same reference tissue sites 23 despite the differences of origin within the kidney. 24 25 One additional question we assessed is how many normal samples are sufficient for proper 1 disease signature-related analyses? We found that even a relatively low number of normal 2 samples may be sufficient for calculating differential expression. For bladder urothelial cancer, for 3 example, the autoencoder selected the bladder GTEx site which consists of only nine tissue 4 samples ( Figure 1B) for a correlation of 0.924; filtering for tissues above the 25th percentile left 5 only seven tissue samples for a correlation of 0.926. When we used a strategy that selected more 6 tissues, i.e. using autoencoder top 50 method, 50 sample tissues were used (9 from bladder and 7 41 from other top correlated sites), which produced a slight drop of correlation to 0.847. This 8 indicates that even a relatively low number of reference tissue samples may provide a robust 9 match. 10 11 Finally, we assessed whether it is a better strategy overall to select all samples from the same 12 tissue site as the cancer of interest or only those that are correlated to the tumor sample. We 13 found that the samples producing the best performance are sites where the tumor developed or 14 a closely related site. However, when it is not possible to use such sites (e.g., when there are no 15 available data), it is feasible to use top correlated tissues as seen from the top 50 methods. 16
However, we found that for some cancers, even choosing top correlated sites can still produce 17 erratic results, such as in the case of lung squamous cell cancer. In this case, the correlations for 18 all non-random methods were between 0.1 -0.3 was not even able to beat the random tissue 19 selection ( Supplementary Table 1 ). Along these lines, we evaluated differential expression 20 similarity using samples from a different origin than the cancer of interest. For example, in two 21 kidney cancers, Kidney Papillary Carcinoma and Kidney Chromophobe the kidney cortex were 22 computed as the top site, for Head and Neck carcinoma the esophagus-mucosa was the top site. 23
Their high correlation with case-control >0.8 indicates that choosing sites at different origin but 24 proximal to the cancer will provide good disease signature ( Supplementary Table 1 ). 25 26 13 Assign normal tissues for cancers with low case-control pairs 1 2 Since there were 18 cancers with insufficient number of adjacent normal tissues, we use our 3 computational approach to assign a primary site for each. Of the 18 cancers, the autoencoder 4 method was able to determine 10 correct sites, whereas using the top 5000 varying genes only 5 produced 4 correct sites (Figure 8 ). This suggests an autoencoder can select proper samples to 6 create disease signatures for those cancers. 7
Conclusions 8
In the current study, we evaluated the nuances of proper reference tissue selection for disease 9 signature-related analyses. Furthermore, we assessed the benefit of using state-of-the-art 10 methodologies, namely deep learning via an autoencoder strategy, to enhance performance of 11 identifying ideal reference tissues for cancers of interest. 12
13
The findings from our study will significantly enhance probing disease biology through gene 14 signatures. As the cost of sequencing is rapidly decreasing, it becomes very common to profile 15 disease samples of interest, however, collecting matched normal tissues from patients is difficult 16 in many instances. Our analysis confirms that GTEx, the largest cohort of normal samples, can 17 serve as a source of reference normal tissues in cancer research. In the current study, we chose 18 to focus on cancer because we have plenty of adjacent tissues that can be used as a benchmark. 19
We expect that the methods and findings from our study can be extended for cancer subtypes or 20 other non-cancer research as well. However, a few caveats have to be considered. First, all RNA-21
Seq data have to be processed in the same pipeline in order to mitigate batch effects. Second, 22 some disease samples may have no relevant normal tissue samples because of diverse cellular 23 14 composition. This limitation may be addressed by using cellular decomposition techniques or 1 single cell data. 2 3 Based on the success of this study, we have some future works that we are exploring. Although 4 we show the potential of using autoencoder for feature selection, we have not fully optimized the 5 model for tissue selection. In our exploratory studies, we found that encoded features are very 6 sensitive to network architecture and parameters, although it does not affect the results in the 7 computation of tissue of origin. For example, when we changed learning rate from 0.0002 to 8 0.005, batch size from 128 to 64, dropout rate from 0.2 to 0.1, LeakyReLU negative slope from 9 0.2 to 0.1, respectively, the average correlation between the new features and the default features 10 changed to 0.219, 0.069, 0.354, and 0.219 ( Supplementary Table 2 ). Interestingly, while a new 11 layer was added into the network, the average correlation even decreased to -0.01. However, 12 while using new features to compute tissue of origin, we observed that all new features could 13 clearly separate the first top site and the second top site. For example, in liver and bladder 14 cancers, liver and bladder are predicted as the top site respectively, and the correlation with the 15 top site is much higher than that with the second site ( Supplementary Table 2) . Surprisingly, when 16 the feature size was reduced from 64 and 32 or two new layers were added, the top site of 17 bladder cancer was incorrectly predicted. In short, given the complexity of neural networks, 18 additional effort should be made to optimize the model, nevertheless, we indeed demonstrate the 19 superiority of deep learning models in this work. 20 21 Furthermore, in addition to using gene expression as features, we will explore adding other cancer 22 specific features including presence of mutations and copy number variation. The autoencoder 23 strategy would be able to manage such diverse feature types. We also plan to determine whether 24 changing the order of workflow, such as removing outliers first, might improve this analysis. In 25 addition, as adjacent cancer normal tissues are sampled near the cancer site, some of these 26 tissues may contain cancer cells and thus have some expression of cancer [17] , which may require 1 further investigation. We will further explore our approach to study pediatric cancers (available in 2 TARGET), where adjacent normal tissues are even more scarce. Table 1 : Consensus sequence and gene rank correlation with case-control pairs 16 using different methods. Differentially expressed genes were selected using adjusted p < 0.001 17 and absolute log fold change > 1. Consensus sequences are defined as overlapping differential 18 expression sequences with same directionality in log fold change. Rank correlation is the 19 Spearman's rank correlation of differential expression (fold change) between the consensus 20 sequences computed from multiple methods (see workflow) and case-control pairs. Unless 21 otherwise stated all rank correlation have p values < 0.01. 22 23 21 Supplemental 
